Presentation is loading. Please wait.

Presentation is loading. Please wait.

Figure 1 Potential interactions between aspirin, P2Y12 inhibitors, and proton pump inhibitors in patients ... Figure 1 Potential interactions between aspirin,

Published byEmma Simons Modified over 5 years ago

Similar presentations

Presentation on theme: "Figure 1 Potential interactions between aspirin, P2Y12 inhibitors, and proton pump inhibitors in patients ... Figure 1 Potential interactions between aspirin,"— Presentation transcript:

1 Figure 1 Potential interactions between aspirin, P2Y12 inhibitors, and proton pump inhibitors in patients ... Figure 1 Potential interactions between aspirin, P2Y<sub>12</sub> inhibitors, and proton pump inhibitors in patients with myocardial infarction. ADP, adenosine diphosphate; ATPase, adenosine triphosphatase (proton pump); CAM, clopidogrel active metabolite; Cl<sup>–</sup>, chloride ion; COX1, cyclo-oxygenase 1; DAPT, dual antiplatelet therapy; H<sup>+</sup>, hydrogen ion (proton); HCO3–, bicarbonate ion; K<sup>+</sup>, potassium ion; Mg<sup>2+</sup>, magnesium ion; PAM, prasugrel active metabolite; P2Y<sub>12</sub>, platelet ADP receptor; PGE<sub>2</sub>, prostaglandin E<sub>2</sub>; TAM, ticagrelor active metabolite; TPα, thromboxane receptor α; TXA<sub>2</sub>, thromboxane A<sub>2</sub>. Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) For permissions, please article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model ( Eur Heart J, ehz102, The content of this slide may be subject to copyright: please see the slide notes for details.

Download ppt "Figure 1 Potential interactions between aspirin, P2Y12 inhibitors, and proton pump inhibitors in patients ... Figure 1 Potential interactions between aspirin,"

Similar presentations

Figure 1 Rates of complications and mortality during index admission for atrial fibrillation ablation for the overall ... Figure 1 Rates of complications.

Figure 1 Rates of complications and mortality during index admission for atrial fibrillation ablation for the overall ... Figure 1 Rates of complications.
Figure 1 Subject phenotypes and most common genotype in subjects enrolled in THAOS in continental Western Europe. Data ... Figure 1 Subject phenotypes.

Figure 1 Subject phenotypes and most common genotype in subjects enrolled in THAOS in continental Western Europe. Data ... Figure 1 Subject phenotypes.
Figure 1 Overall lag-cumulative exposure–response relationships between air temperature and myocardial infarction ... Figure 1 Overall lag-cumulative exposure–response.

Figure 1 Overall lag-cumulative exposure–response relationships between air temperature and myocardial infarction ... Figure 1 Overall lag-cumulative exposure–response.
Unless provided in the caption above, the following copyright applies to the content of this slide: © 2019 European Society of Cardiology and British Pharmacological.

Unless provided in the caption above, the following copyright applies to the content of this slide: © 2019 European Society of Cardiology and British Pharmacological.
Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.
Figure 1 Data-selection process

Figure 1 Data-selection process
Figure 1 Flow diagram detailing the systematic review process.

Figure 1 Flow diagram detailing the systematic review process.
Figure 1 Multivariable-adjusted predictors of PAC

Figure 1 Multivariable-adjusted predictors of PAC
Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.
Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.
Figure 1 Unadjusted Kaplan–Meier curves for all-cause mortality in the transcatheter mitral valve repair and ... Figure 1 Unadjusted Kaplan–Meier curves.

Figure 1 Unadjusted Kaplan–Meier curves for all-cause mortality in the transcatheter mitral valve repair and ... Figure 1 Unadjusted Kaplan–Meier curves.
Figure 1 Mechanism of mortality benefit associated with radial access

Figure 1 Mechanism of mortality benefit associated with radial access
Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.
Figure 1 Number of percutaneous coronary interventions (PCI) in mainland China, 2017 (total 753 142). Data from China ... Figure 1 Number of percutaneous.

Figure 1 Number of percutaneous coronary interventions (PCI) in mainland China, 2017 (total 753 142). Data from China ... Figure 1 Number of percutaneous.
Figure 1 ELECTRa registry patient flow diagram presenting the proportion of patients of the total enrolled patient ... Figure 1 ELECTRa registry patient.

Figure 1 ELECTRa registry patient flow diagram presenting the proportion of patients of the total enrolled patient ... Figure 1 ELECTRa registry patient.
Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.
Figure 1 The Kaplan–Meier curves of time to death post first hospitalization. hosp, hospitalization. Unless provided in the caption above, the following.

Figure 1 The Kaplan–Meier curves of time to death post first hospitalization. hosp, hospitalization. Unless provided in the caption above, the following.
Figure 1 Sources of uncertainty introduced in each stage of the standard modelling approach for estimating ... Figure 1 Sources of uncertainty introduced.

Figure 1 Sources of uncertainty introduced in each stage of the standard modelling approach for estimating ... Figure 1 Sources of uncertainty introduced.
AHA: American Heart Association; ALT: ...

AHA: American Heart Association; ALT: ...
Figure 1. Serum ceftazidime concentrations following intravenous administration. Unless provided in the caption above, the following copyright applies.

Figure 1. Serum ceftazidime concentrations following intravenous administration. Unless provided in the caption above, the following copyright applies.

Similar presentations

Ads by Google